Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides as Dipeptidyl Peptidase 1 Inhibitors

AstraZeneca AB

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 16 of these applications claim priority to application 61/931,090, filed Jan 24, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Patent	Title	Holder	Status	Expires	Time remaining	Confidence
US 9,815,805	Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides as Dipeptidyl Peptidase 1 Inhibitors AstraZeneca AB In force Term ends Jan 21, 2035 · Low confidence	AstraZeneca AB	In force	Term ends Jan 21, 2035	Term ends Jan 21, 2035	Low confidence
US 10,287,258	Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides as Dipeptidyl Peptidase 1 Inhibitors AstraZeneca AB In force Term ends Jan 21, 2035 · Low confidence	AstraZeneca AB	In force	Term ends Jan 21, 2035	Term ends Jan 21, 2035	Low confidence
US 10,669,245	Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides as Dipeptidyl Peptidase 1 Inhibitors AstraZeneca AB In force Term ends Jan 21, 2035 · Low confidence	AstraZeneca AB	In force	Term ends Jan 21, 2035	Term ends Jan 21, 2035	Low confidence
US 11,117,874	Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides as Dipeptidyl Peptidase 1 Inhibitors AstraZeneca AB In force Term ends Jan 21, 2035 · Low confidence	AstraZeneca AB	In force	Term ends Jan 21, 2035	Term ends Jan 21, 2035	Low confidence
US 11,655,221	Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides as Dipeptidyl Peptidase 1 Inhibitors AstraZeneca AB In force Term ends Jan 21, 2035 · Low confidence	AstraZeneca AB	In force	Term ends Jan 21, 2035	Term ends Jan 21, 2035	Low confidence
US 11,655,222	Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides as Dipeptidyl Peptidase 1 Inhibitors AstraZeneca AB In force Term ends Jan 21, 2035 · Low confidence	AstraZeneca AB	In force	Term ends Jan 21, 2035	Term ends Jan 21, 2035	Low confidence
US 11,655,223	Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides as Dipeptidyl Peptidase 1 Inhibitors AstraZeneca AB In force Term ends Jan 21, 2035 · Low confidence	AstraZeneca AB	In force	Term ends Jan 21, 2035	Term ends Jan 21, 2035	Low confidence
US 11,655,224	Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides as Dipeptidyl Peptidase 1 Inhibitors AstraZeneca AB In force Term ends Jan 21, 2035 · Low confidence	AstraZeneca AB	In force	Term ends Jan 21, 2035	Term ends Jan 21, 2035	Low confidence
US 11,667,615	Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides as Dipeptidyl Peptidase 1 Inhibitors AstraZeneca AB In force Term ends Jan 21, 2035 · Low confidence	AstraZeneca AB	In force	Term ends Jan 21, 2035	Term ends Jan 21, 2035	Low confidence
US 11,673,871	Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides as Dipeptidyl Peptidase 1 Inhibitors AstraZeneca AB In force Term ends Jan 21, 2035 · Low confidence	AstraZeneca AB	In force	Term ends Jan 21, 2035	Term ends Jan 21, 2035	Low confidence
9 more patents in this group · Pro

10 of 19 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Pro members see all 19.

Upgrade to Pro

16 of these are in force and held by AstraZeneca AB.

Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.